Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Figure out How to Get the Most Familiar Drive for Seniors in SUVs - 2Esteem Stuffed Gaming Workstations to Consider
- 3I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away
- 4The best ice packs for coolers of 2026, tested and reviewed
- 5Central African Republic's president sworn in for a third term after disputed election
- Spain breaks jobs record with 22 million Social Security contributors
- Father and son spending Christmas together after health scares
- Our 10 favorite Space.com reader astronomy photos of 2025
- Weeks-Long Australian LNG Outage Will Further Tighten Supply
- Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- The Main 20 Gaming Control center Ever
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Cyprus urges hotels to open up, pours funding into tourism
- 'You're no longer my sister' - rows erupt as war divides Iranian families
